Trifluridin/tipiracil in treatment of refractory metastatic colorectal cancer - early clinical experience
Abstract
Aim: A retrospective evaluation of efficacy and toleration of trifluridin/tipiracil. Patients and methods: A total of 18 patients with refractory metastatic colorectal cancer, treated with trifluridin/tipiracil, were evaluated.
Results: At the time of this analysis, 13 patients completed the treatment and 5 patients in the treatment continue. Median of cycles administered to patients with completed treatment was 3 (2-3) cycles.
According to the restaging CT examination after 3 cycles of treatment, 10 patients had progressive disease and one patient, who continues treatment, stable disease. Ten patients discontinued treatment due to disease progression, two because of performance status deterioration, and 1 patient due to thrombocytopenia.
Median of PFS was 3,4 (95% CI: 2,9-4,0) months. Median of overall survival has not yet been achieved.
Leucopenia grade 3 occurred in 3 patients, anemia grade 3 in one patient, thrombocytopenia grade 4 in one patient. Elevations of AST grade 2, ALP grade 3 and GGT grade 4 in one patient.
Incipient pneumonia with hospitalization was in one patient. Conclusion: The treatment with trifluridin/tipiracil we evaluate positively.
Trifluridin/tipiracil is an integral part of treatment in patients with refractory metastatic colorectal cancer.